Insider Trading March 19, 2026

IEH Corp Director Reduces Stake, Selling 1,000 Shares for $17,697

Director Gerald E. Chafetz trims position across two days as stock trades near its 52-week high

By Avery Klein IEHC
IEH Corp Director Reduces Stake, Selling 1,000 Shares for $17,697
IEHC

Gerald E. Chafetz, a director of IEH Corp (NASDAQ:IEHC), disposed of 1,000 shares of common stock in transactions on March 17 and March 18, 2026, raising $17,697. The sales were disclosed on a Form 4 filed with the Securities and Exchange Commission. Following the disposition, Chafetz holds 1,000 shares directly and retains stock option exposures with strike prices of $6.01 and $8.28 maturing in 2033 and 2035 respectively. The stock is trading near a 52-week high while recent analysis from InvestingPro flags valuation and profitability considerations.

Key Points

  • Director Gerald E. Chafetz sold a total of 1,000 IEH Corp shares across March 17-18, 2026, generating $17,697.
  • After the trades, Chafetz directly owns 1,000 shares and retains options to purchase 10,000 shares in two tranches expiring in 2033 and 2035.
  • IEH Corp shares traded at $17.86, close to a 52-week high of $19.60, with a 123% one-year return but a 9.2% decline over the past week; InvestingPro flags valuation and profitability concerns.

Transaction overview

IEH Corp director Gerald E. Chafetz reported the sale of 1,000 shares of common stock in a Form 4 filed with the Securities and Exchange Commission. The dispositions took place over two consecutive trading days, March 17 and March 18, 2026, and generated total proceeds of $17,697.

On March 17, Chafetz sold 500 shares at $17.3922 per share. After that transaction he directly owned 1,500 shares of IEH Corp. The next day, March 18, he sold 498 shares at $18.00 per share and 2 shares at $18.50 per share, reducing his direct holdings to 1,000 shares.

Market context

At the time of the filing, IEH Corp shares were quoted at $17.86, trading close to the company's 52-week high of $19.60. The stock had declined 9.2% over the prior week but remained up 123% over the past year. Analysis from InvestingPro indicated that IEHC appears overvalued relative to its Fair Value, and InvestingPro Tips flagged ongoing profitability challenges. The platform notes that investors can access additional ProTips and a broader set of financial metrics for further context.

Option holdings

In addition to his direct shareholdings, Chafetz holds stock options tied to IEH Corp. He has options to purchase 5,000 shares at an exercise price of $6.01 that expire on May 8, 2033, and a separate grant of options to purchase 5,000 shares at an exercise price of $8.28 that expire on May 8, 2035.

Implications and notes

The Form 4 filing records the director-level sales and the remaining direct and derivative positions. The disclosure provides a snapshot of insider activity while also outlining option exposures that remain in place. Beyond the transaction details and InvestingPro's valuation and profitability commentary, the filing does not include additional explanation for the sales.


Data and sources

The transaction details above are taken from the Form 4 filing submitted to the Securities and Exchange Commission and the market and analysis figures cited are those reported in the filing-related summary.

Risks

  • The filing documents a director sale but does not provide a reason for the transaction, leaving uncertainty about intent and timing - impacts investor interpretation of insider signaling.
  • InvestingPro's note on overvaluation relative to Fair Value introduces valuation risk for investors considering exposure to IEHC - relevant to equity markets and semiconductor-related investors.
  • InvestingPro Tips highlight ongoing profitability challenges for IEHC, creating operational risk that could affect future stock performance and investor returns.

More from Insider Trading

Revolution Medicines R&D Chief Sells $427,964 in Shares; Company Posts Q4 Loss Above Estimates Mar 19, 2026 Revolution Medicines CEO Sells $1.28 Million in Shares Under Pre‑Arranged Plan Mar 19, 2026 Revolution Medicines COO Disposes $455,918 in Stock as Shares Trade Near Yearly Peak Mar 19, 2026 Pale Fire Capital-led group buys $18.3M of Phreesia stock, raises stake to 7.65M shares Mar 19, 2026 Revolution Medicines General Counsel Disposes of Nearly $292,000 in RVMD Shares Mar 19, 2026